HighGravityData
Companies / Medical devices & equipment / PODD

Insulet

PODD · Medical devices & equipment sector group
Guidance from Insulet’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Current guidance
31 items
Releases tracked
8
Latest release
Aug 5, 2026
Data checked
Aug 5, 2026
On this page:Latest changes·Current guidance·Your sector group·History

What changed in the Aug 5, 2026 release

Each item compared with the same item in the previous release (May 6, 2026). Values in quotation marks are the company’s words.

New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
ChangeMetricPeriodPreviousNowSource
NewDrug Delivery Revenue Growth - Constant Currencyfor Q3 FY2026—“~(20%)”Filing ↗
RaisedInternational Omnipod Revenue Growth - Constant Currencyfor FY2026“26% - 28%”“30% - 32%”Filing ↗
NewInternational Omnipod Revenue Growth - Constant Currencyfor Q3 FY2026—“28% - 30%”Filing ↗
NewInternational Omnipod Revenue Growth - Currency Impactfor Q3 FY2026—“(2)%”Filing ↗
RaisedInternational Omnipod Revenue Growth - GAAPfor FY2026“29% - 31%”“33% - 35%”Filing ↗
NewInternational Omnipod Revenue Growth - GAAPfor Q3 FY2026—“26% - 28%”Filing ↗
LoweredTotal Omnipod Revenue Growth - Constant Currencyfor FY2026“22% - 24%”“21% - 23%”Filing ↗
NewTotal Omnipod Revenue Growth - Constant Currencyfor Q3 FY2026—“18% - 20%”Filing ↗
NewTotal Omnipod Revenue Growth - Currency Impactfor FY2026—“1%”Filing ↗
NewTotal Omnipod Revenue Growth - Currency Impactfor Q3 FY2026—“(0.5)%”Filing ↗
LoweredTotal Omnipod Revenue Growth - GAAPfor FY2026“23% - 25%”“22% - 24%”Filing ↗
NewTotal Omnipod Revenue Growth - GAAPfor Q3 FY2026—“17.5% - 19.5%”Filing ↗
LoweredTotal Revenue Growth - Constant Currencyfor FY2026“21% - 23%”“20% - 22%”Filing ↗
NewTotal Revenue Growth - Constant Currencyfor Q3 FY2026—“17.5% - 19.5%”Filing ↗
LoweredTotal Revenue Growth - GAAPfor FY2026“22% - 24%”“21% - 23%”Filing ↗
NewTotal Revenue Growth - GAAPfor Q3 FY2026—“17% - 19%”Filing ↗
LoweredU.S. Omnipod Revenue Growth - Constant Currencyfor FY2026“20% - 22%”“17% - 19%”Filing ↗
NewU.S. Omnipod Revenue Growth - Constant Currencyfor Q3 FY2026—“14% - 16%”Filing ↗
NewAdjusted EPS Growthfor Q3 FY2026—“>30%”Filing ↗
NewAdjusted Operating Marginfor Q3 FY2026—“~100 bps YoY expansion”Filing ↗
NewDrug Deliveryfor Q3 FY2026—“~(20%)”Filing ↗
NewInternational Omnipodfor Q3 FY2026—“28% - 30%”Filing ↗
RaisedInternational Omnipodfor FY2026“26% - 28%”“30% - 32%”Filing ↗
NewTotal Omnipodfor Q3 FY2026—“18% - 20%”Filing ↗
LoweredTotal Omnipodfor FY2026“22% - 24%”“21% - 23%”Filing ↗
ReiteratedInternational Omnipod Revenue Growth - Currency Impactfor FY2026“3%”“3%”Filing ↗
ReiteratedAdjusted EPS Growthfor FY2026“>25%”“>25%”Filing ↗

Current guidance

Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.

Current fiscal year
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
Drug Delivery Revenue Growth - Constant Currency“~(20%)”for Q3 FY2026Company-definedAug 5, 20261Filing ↗
International Omnipod Revenue Growth - Constant Currency“30% - 32%”for FY2026Company-definedMay 6, 20262Filing ↗
International Omnipod Revenue Growth - Constant Currency“28% - 30%”for Q3 FY2026Company-definedAug 5, 20261Filing ↗
International Omnipod Revenue Growth - Currency Impact“3%”for FY2026GAAP-tiedMay 6, 20262Filing ↗
International Omnipod Revenue Growth - Currency Impact“(2)%”for Q3 FY2026GAAP-tiedAug 5, 20261Filing ↗
International Omnipod Revenue Growth - GAAP“33% - 35%”for FY2026GAAP-tiedMay 6, 20262Filing ↗
International Omnipod Revenue Growth - GAAP“26% - 28%”for Q3 FY2026GAAP-tiedAug 5, 20261Filing ↗
Total Omnipod Revenue Growth - Constant Currency“21% - 23%”for FY2026Company-definedMay 6, 20262Filing ↗
Total Omnipod Revenue Growth - Constant Currency“18% - 20%”for Q3 FY2026Company-definedAug 5, 20261Filing ↗
Total Omnipod Revenue Growth - Currency Impact“1%”for FY2026GAAP-tiedAug 5, 20261Filing ↗
Total Omnipod Revenue Growth - Currency Impact“(0.5)%”for Q3 FY2026GAAP-tiedAug 5, 20261Filing ↗
Total Omnipod Revenue Growth - GAAP“22% - 24%”for FY2026GAAP-tiedMay 6, 20262Filing ↗
Total Omnipod Revenue Growth - GAAP“17.5% - 19.5%”for Q3 FY2026GAAP-tiedAug 5, 20261Filing ↗
Total Revenue Growth - Constant Currency“20% - 22%”for FY2026Company-definedMay 6, 20262Filing ↗
Total Revenue Growth - Constant Currency“17.5% - 19.5%”for Q3 FY2026Company-definedAug 5, 20261Filing ↗
Total Revenue Growth - GAAP“21% - 23%”for FY2026GAAP-tiedMay 6, 20262Filing ↗
Total Revenue Growth - GAAP“17% - 19%”for Q3 FY2026GAAP-tiedAug 5, 20261Filing ↗
U.S. Omnipod Revenue Growth - Constant Currency“17% - 19%”for FY2026Company-definedMay 6, 20262Filing ↗
U.S. Omnipod Revenue Growth - Constant Currency“14% - 16%”for Q3 FY2026Company-definedAug 5, 20261Filing ↗
Adjusted EPS Growth“>30%”for Q3 FY2026Company-definedAug 5, 20261Filing ↗
Adjusted EPS Growth“>25%”for FY2026Company-definedFeb 18, 20262Filing ↗
Adjusted Operating Margin“~100 bps YoY expansion”for Q3 FY2026Company-definedAug 5, 20261Filing ↗
Adjusted Operating Margin“~100 bps YoY expansion”for FY2026Company-definedFeb 18, 20261Filing ↗
Drug Delivery“~(20%)”for Q3 FY2026Company-definedAug 5, 20261Filing ↗
Drug Delivery“~(50)%”for FY2026Company-definedFeb 18, 20261Filing ↗
International“24% -26%”for FY2026Company-definedFeb 18, 20261Filing ↗
International Omnipod“28% - 30%”for Q3 FY2026Company-definedAug 5, 20261Filing ↗
International Omnipod“30% - 32%”for FY2026Company-definedMay 6, 20262Filing ↗
Share repurchase program“up to $125 million”for FY2026Declared actionMay 8, 20251Filing ↗
Stock repurchase program authorization“up to $125 million”for FY2026Declared actionMay 8, 20251Filing ↗
Total Omnipod“18% - 20%”for Q3 FY2026Company-definedAug 5, 20261Filing ↗
Total Omnipod“21% - 23%”for FY2026Company-definedMay 6, 20262Filing ↗
Total Omnipod Products“21% - 23%”for FY2026Company-definedFeb 18, 20261Filing ↗
No period stated
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
Share repurchase authorization increase“$350 million”—Declared actionFeb 18, 20261Filing ↗

How one item moved

Drug Delivery, for FY2025 — every statement across the year, each linked to its filing.

May 8, 2025
New
“(35)% - (25)%”
Filing ↗
Aug 7, 2025
Narrowed
“(30)% - (25)%”
Filing ↗
Nov 6, 2025
Raised
“(15)% - (10)%”
Filing ↗

How your Medical devices & equipment sector group guides

12 companies in Medical devices & equipment. What they guide on, and who reported this season.

Most-guided metric families
Revenue
9
Organic growth
8
Adjusted EPS
8
Buybacks
6
GAAP EPS
5
Operating margin
4
Dividends
3
Gross margin
2
This season’s releases
MedtronicSep 1, 20263 changes
Becton DickinsonAug 6, 20264 changes
ResMedAug 6, 20260 changes
InsuletAug 5, 202625 changes
Zimmer BiometAug 5, 20263 changes
DexComJul 30, 20263 changes
StrykerJul 30, 20262 changes
Boston ScientificJul 29, 20265 changes
Get this for your own peer set — Peer Guidance Briefing, $3,000.

Full history

Every metric, every release, eight quarters — the complete record as one table.

MetricFY2026FY2025FY2024No period
Drug Delivery revenue growth—1 statement1 statement—
Drug Delivery Revenue Growth - Constant Currency1 statement———
Drug Delivery Revenue Growth (Constant Currency)1 statement4 statements2 statements—
International Omnipod Revenue Growth - Constant Currency3 statements———
International Omnipod Revenue Growth - Currency Impact3 statements———
The full record for Insulet and its Medical devices & equipment peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.

Filings

The 8 earnings releases this page is built from.

FiledFiscal periodAccessionGuidance items
Aug 5, 2026FY2026 Q20001145197-26-00016727Open filing ↗
May 6, 2026FY2026 Q10001145197-26-00010025Open filing ↗
Feb 18, 2026FY2025 Q40001145197-26-00002611Open filing ↗
Nov 6, 2025FY2025 Q30001145197-25-00006711Open filing ↗
Aug 7, 2025FY2025 Q20001145197-25-00003721Open filing ↗
May 8, 2025FY2025 Q10001145197-25-00002113Open filing ↗
Feb 20, 2025FY2024 Q40001145197-25-00000621Open filing ↗
Nov 7, 2024FY2024 Q30001145197-24-00004319Open filing ↗
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error